PROM1 and prostate cancer: CD133 selection has been used to enrich a population of normal prostate epithelial cells capable of forming acinar-like structures as xenografts, and to derive a population of prostate cancer cells with a higher tumorigenic capacity in vitro than its negative counterpart [17].